Developing immunotherapy strategies in the treatment of prostate cancer

Asian Journal of Urology, 2016, 3 (4): 278-285 doi:

Review

Current Issue | Archive | Adv Search

Developing immunotherapy strategies in the treatment of prostate cancer

James L. Gulley, Ravi A. Madan

Genitourinary Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA

Abstract
Related Citation (15)

Download:

HTML

PDF (1786KB)
Export: BibTeX | EndNote (RIS)

Abstract The clinical development of immunotherapy has gained significant impetus in recent years across the field of medical oncology. Mounting preclinical and clinical data have demonstrated the potential of immune-based treatments to augment anti-tumor immune responses. With one of the first modern immunotherapies approved in prostate cancer and multiple others in late stage development, immune treatment strategies need to be optimized to ensure the best clinical outcomes. Combination strategies with androgen deprivation therapy, anti-androgen therapy, radiation and chemotherapy have demonstrated the potential maximize immune response in prostate cancer patients. These combinations are currently being evaluated in clinical trials at every stage of prostate cancer from the newly diagnosed to the most advanced stages. Data from these studies will provide guidance for the future clinical implementation of immunotherapy in prostate cancer.

Key words： Prostate cancer Immunotherapy Combination therapies

Received: 11 July 2016 Published: 02 November 2016

	Service
	E-mail this article
	Add to citation manager
	E-mail Alert
	Articles by authors
	James L. Gulley
	Ravi A. Madan

TRENDMD:

Cite this article:

James L. Gulley,Ravi A. Madan. Developing immunotherapy strategies in the treatment of prostate cancer[J]. Asian Journal of Urology, 2016, 3(4): 278-285.

URL:

http://www.ajurology.com/EN/ OR http://www.ajurology.com/EN/Y2016/V3/I4/278

[1]	Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T immunotherapy for castrationresistant prostate cancer. N Engl J Med 2010;363:411-22.
[2]	Madan RA, Gulley JL. Prospects for the future of prostate cancer vaccines. Expert Rev Vaccines 2016;15:271-4.
[3]	So-Rosillo R, Small EJ. Sipuleucel-T (APC8015) for prostate cancer. Expert Rev Anticancer Ther 2006;6:1163-7.
[4]	Sheikh NA, Petrylak D, Kantoff PW, Dela Rosa C, Stewart FP, Kuan LY, et al. Sipuleucel-T immune parameters correlate with survival:an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer. Cancer Immunol Immunother 2013;62:137-47.
[5]	George DJ, Nabhan C, DeVries T, Whitmore JB, Gomella LG. Survival outcomes of sipuleucel-T phase III studies:impact of control-arm cross-over to salvage immunotherapy. Cancer Immunol Res 2015;3:1063-9.
[6]	Madan RA, Gulley JL, Fojo T, Dahut WL. Therapeutic cancer vaccinesinprostatecancer:theparadoxofimprovedsurvivalwithout changes in time to progression. Oncologist 2010;15:969-75.
[7]	Small EJ, Schellhammer PF, Higano CS, Redfern CH, Nemunaitis JJ, Valone FH, et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 2006;24:3089-94.
[8]	Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improvedsurvival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-23.
[9]	Fong L, Carroll P, Weinberg V, Chan S, Lewis J, Corman J, et al. Activated lymphocyte recruitment into the tumor microenvironment following preoperative sipuleucel-T for localized prostate cancer. J Natl Cancer Inst 2014;106.
[10]	Walunas TL, Lenschow DJ, Bakker CY, Linsley PS, Freeman GJ, Green JM, et al. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1994;1:405-13.
[11]	Kwon ED, Drake CG, Scher HI, Fizazi K, Bossi A, van den Eertwegh AJ, et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043):a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol 2014;15:700-12.
[12]	Slovin SF, Higano CS, Hamid O, Tejwani S, Harzstark A, Alumkal JJ, et al. Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer:results from an open-label, multicenter phase I/II study. Ann Oncol 2013;24:1813-21.
[13]	Schellhammer PF, Chodak G, Whitmore JB, Sims R, Frohlich MW, Kantoff PW. Lower baseline prostate-specific antigen is associated with a greater overall survival benefit from sipuleucel-T in the immunotherapy for prostate adenocarcinoma treatment (IMPACT) trial. Urology 2013;81:1297-302.
[14]	Gulley JL, Arlen PM, Madan RA, Tsang KY, Pazdur MP, Skarupa L, et al. Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer. Cancer Immunol Immunother 2010;59:663-74.
[15]	Sharifi N, Gulley JL, Dahut WL. An update on androgen deprivation therapy for prostate cancer. Endocr Relat Cancer 2010;17:R305-15.
[16]	Drake CG, Doody AD, Mihalyo MA, Huang CT, Kelleher E, Ravi S, et al. Androgen ablation mitigates tolerance to a prostate/-prostate cancer-restricted antigen. Cancer Cell 2005;7:239-49.
[17]	Mercader M, Bodner BK, Moser MT, Kwon PS, Park ES, Manecke RG, et al. T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer. Proc Natl Acad Sci USA 2001;98:14565-70.
[18]	Williams KM, Lucas PJ, Bare CV, Wang J, Chu YW, Tayler E, et al. CCL25 increases thymopoiesis after androgen withdrawal. Blood 2008;112:3255-63.
[19]	Madan RA, Hakim F, Jochems C, Heery CR, O'sullivan GC, Singh H, et al. Impact of androgen deprivation therapy on the thymus and the production of naïve T-cells. J Immunother Cancer 2013;1(Suppl 1):P83.
[20]	Antonarakis ES, Kibel AS, Adams G, Krash LI, Elfiky A, Shore ND, et al. A randomized phase II study evaluating the optimal sequencing of sipuleucel-T and androgen deprivation therapy in biochemically recurrent prostate cancer:immune results. J Clin Oncol 2013;31. suppl; abstr 5016.
[21]	Basch E, Loblaw DA, Oliver TK, Carducci M, Chen RC, Frame JN, et al. Systemic therapy in men with metastatic castration-resistant prostate cancer:American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline. J Clin Oncol 2014;32:3436-48.
[22]	Ardiani A, Gameiro SR, Kwilas AR, Donahue RN, Hodge JW. Androgen deprivation therapy sensitizes prostate cancer cells to T-cell killing through androgen receptor dependent modulation of the apoptotic pathway. Oncotarget 2014;5:9335-48.
[23]	Madan RA, Donahue RN, Singh H, Karzi F, Theoret MR, Heery CR, et al. Clinical and immunologic impact of short course enzalutamide without androgen deprivation therapy for biochemically recurrent prostate cancer. J Clin Oncol 2016;34. suppl 2S; abstr 214.
[24]	Poleszczuk JT, Luddy KA, Prokopiou S, Robertson-Tessi M, Moros EG, Fishman M, et al. Abscopal benefits of localized radiotherapy depend on activated T-cell trafficking and distribution between metastatic lesions. Cancer Res 2016;76:1009-18.
[25]	Postow MA, Callahan MK, Barker CA, Yamada Y, Yuan J, Kitano S, et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med 2012;366:925-31.
[26]	Ahmed MM, Guha C, Hodge JW, Jaffee E. Immunobiology of radiotherapy:new paradigms. Radiat Res 2014;182:123-5.
[27]	Gameiro SR, Ardiani A, Kwilas A, Hodge JW. Radiation-induced survival responses promote immunogenic modulation to enhance immunotherapy in combinatorial regimens. Oncoimmunology 2014;3:e28643.
[28]	Gulley JL, Arlen PM, Bastian A, Morin S, Marte J, Beetham P, et al. Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer. Clin Cancer Res 2005;11:3353-62.
[29]	Heery CR, Madan RA, Stein MN, Stadler WM, Dipaola RS. Samarium-153-EDTMP (Quadramet) with or without vaccine in metastatic castration-resistant prostate cancer:a randomized phase 2 trial. OncoTarget 2016. http://dx.doi.org/10.18632/oncotarget.10883[Epub ahead of print].
[30]	Sartor O, Reid RH, Hoskin PJ, Quick DP, Ell PJ, Coleman RE, et al. Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer. Urology 2004;63:940-5.
[31]	Parker C, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Fosså SD, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013;369:213-23.
[32]	Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502-12.
[33]	Petrylak DP, Tangen CM, Hussain MH, Lara Jr PN, Jones JA, Taplin ME, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513-20.
[34]	Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med 2015;373:737-46.
[35]	Sandler HM, Hu C, Rosenthal SA, Sartor O, Gomella LG, Amin M, et al. A phase III protocol of androgen suppression (AS) and 3DCRT/IMRT versus AS and 3DCRT/IMRT followed by chemotherapy with docetaxel and prednisone for localized, high-risk prostate cancer (RTOG 0521). J Clin Oncol 2015;33. suppl; abstr LBA5002.
[36]	Sartor O. Cabazitaxel vs. docetaxel in chemotherapy-naive (CN) patients with metastatic castration-resistant prostate cancer. ASCO Annu Meet Abstr 2016.
[37]	Garnett CT, Schlom J, Hodge JW. Combination of docetaxel and recombinant vaccine enhances T-cell responses and antitumor activity:effects of docetaxel on immune enhancement. Clin Cancer Res 2008;14:3536-44.
[38]	Hodge JW, Garnett CT, Farsaci B, Palena C, Tsang KY, Ferrone S, et al. Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death. Int J Cancer 2013;133:624-36.
[39]	Arlen PM, Gulley JL, Parker C, Skarupa L, Pazdur M, Panicali D, et al. A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgenindependent prostate cancer. Clin Cancer Res 2006;12:1260-9.
[40]	Heery CR, Ibrahim NK, Arlen PM, Mohebtash M, Murray JL, Koenig K, et al. Docetaxel alone or in combination with a therapeutic cancer vaccine (PANVAC) in patients with metastatic breast cancer:a randomized clinical trial. JAMA Oncol 2015;1:1087-95.
[41]	Boehm AL, Higgins J, Franzusoff A, Schlom J, Hodge JW. Concurrent vaccination with two distinct vaccine platforms targeting the same antigen generates phenotypically and functionally distinct T-cell populations. Cancer Immunol Immunother 2010;59:397-408.
[42]	van den Eertwegh AJ, Versluis J, van den Berg HP, Santegoets SJ, van Moorselaar RJ, van der Sluis TM, et al. Combined immunotherapy with granulocytemacrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer:a phase 1 dose-escalation trial. Lancet Oncol 2012;13:509-17.
[43]	Madan RA, Mohebtash M, Arlen PM, Vergati M, Rauckhorst M, Steinberg SM, et al. Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostatecancer:aphase 1 dose-escalation trial. Lancet Oncol 2012;13:501-8.
[44]	Strauss J, Madan RA, Gulley JL. Considerations for the combination of anticancer vaccines and immune checkpoint inhibitors. Expert Opin Biol Ther 2016;16:895-901.